Five Prime Therapeutics Inc
Anti-FGFR2 Antibody Formulations
Last updated:
Abstract:
This disclosure relates to a formulation of an anti-fibroblast growth factor receptor 2 (FGFR2) antibody that, in some embodiments, is capable of being stored as a liquid, for example in a ready-to-use form, and that, in some embodiments, may be administered intravenously such as by intravenous (IV) infusion.
Status:
Application
Type:
Utility
Filling date:
4 Oct 2019
Issue date:
13 Jan 2022